Drugs / Allogeneic CD19-STAR T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06321289 | Mar 2024 → Mar 2026 overdue | B-cell non-Hodgkin lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic CD19-STAR T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06321289 ↗ |
| Modality | Cell therapy | “allogeneic CD19-targeting STAR T cell therapy” NCT06321289 ↗ |
| Route | Other | “allogeneic CD19-STAR T cell infusion” NCT06321289 ↗ |
| Target | CD19 | “allogeneic CD19-targeting STAR T cell therapy” NCT06321289 ↗ |